Dipeptidyl peptidase-4 inhibitor use not tied to pneumonia hospitalizations

Dipeptidyl peptidase-4 inhibitor use not tied to pneumonia hospitalizations
Dipeptidyl peptidase-4 inhibitor use not tied to pneumonia hospitalizations

HealthDay News — The use of dipeptidyl peptidase-4 inhibitors is not associated with an increased risk of hospitalization for community-acquired pneumonia, according to study findings published in Diabetes, Obesity and Metabolism.

To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with an increased risk of community-acquired pneumonia, Jean-Luc Faillie, MD, of Jewish General Hospital in Montreal, and colleagues utilized data from the United Kingdom Clinical Practice Research Datalink and Hospital Episodes Statistics database to identify new users of antidiabetic drugs between 2007 and 2012.

Comparisons were made between cases hospitalized for incident community-acquired pneumonia and up to 20 controls who were matched for age, duration of treated diabetes, calendar year, and duration of follow-up.

Of the 49,653 patients included in the cohort, 562 were hospitalized for community-acquired pneumonia during follow-up (incidence rate 5.2/1,000 person-years). Current use of DPP-4 inhibitors was not associated with an increased risk of hospitalized community-acquired pneumonia overall (adjusted OR, 0.80; 95 percent confidence interval, 0.50 to 1.29) or according to duration of use (P for trend=0.57), compared with current use of two or more oral antidiabetic drugs.

"Additional research is needed to assess the association between these drugs and other serious infections," concluded the scientists.

References

  1. Faillie JL et al. Diabetes, Obesity and Metabolism. 2015; doi: 10.1111/dom.12431
Loading links....
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters